Clinical trial NCT02787486: Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
Official title: A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Down Syndrome
Edwards Syndrome
Patau Syndrome
Klinefelter Syndrome
Turner Syndrome
DiGeorge Syndrome
Chromosome Deletion
Aneuploidy
Keywords: Down syndrome
Edwards syndrome
Patau syndrome
Klinefelter syndrome
DiGeorge syndrome
Chromosome Deletion
Aneuploidy
Lead sponsor: Progenity, Inc.
Sponsor class: INDUSTRY
First posted: 2016-06-01
Enrollment: 760
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 54
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: FAMILY_BASED
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All pregnant women undergoing standard maternal serum screening for fetal aneuploidy will be considered for enrollment as well as those with a priori risk factors for fetal aneuploidy.

Brief summary: In January 2007, the American Congress of Obstetricians and Gynecologists (ACOG) revised its guidelines that now recommend physicians are ethically obligated to fully inform all pregnant women that screening for fetal chromosomal abnormalities including biochemical screening tests and invasive procedures such as CVS or amniocentesis is available, regardless of age. Further, it is entirely up to the patient to decide whether or not she wishes to be screened for fetal chromosomal abnormalities without judgment from the physician.

Noninvasive laboratory-developed tests (LDTs) that detect an abnormal amount of maternal and fetal DNA in an expectant mother's blood sample (known as circulating cell-free DNA) are now available. These LDTs have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although LDTs to date have not been subject to U.S. FDA regulation, certification of the laboratory is required under the Clinical Laboratory Improvement Amendments (CLIA) to ensure the quality and validity of the test.

To sample collection study will obtain whole blood specimens from pregnant subjects to be used for development of prenatal assays to assist in the screening for fetal genetic abnormalities, infectious and other diseases, and blood group typing through detection of circulating cell-free DNA extracted from maternal plasma.

Detailed description: Eligible subjects will provide written informed consent after which basic demographic and clinical data will be collected.

Study procedures involve the collection of 50 mL of whole blood at one or more monthly clinic visits (≥25 days apart) from pregnant women (18 to 54 yrs of age) carrying a single fetus of 8 to 22 weeks of gestational age inclusive.

Eligibility criteria: Inclusion Criteria:

* Subject is willing to provide informed consent and comply with study procedures
* Pregnant female, 18 to 54 years of age carrying a singleton fetus of 8 to 22 weeks gestational age
* Willing to provide a study blood sample in accordance with the protocol
* Willing to allow access to her medical records to collect pregnancy outcome information
* Willing to provide consent for release of fetal karyotype if an invasive procedure (CVS or amniocentesis) is performed during the pregnancy
* Subject is known to be at risk for one or more of the following:
* fetal gene and chromosome abnormalities (e.g., T21, T18, T13, microdeletion syndromes, sex chromosome abnormalities)
* congenital fetal infection (e.g. toxoplasmosis, syphilis, HIV, rubella, CMV, HSV)
* irregular blood group antigens (subject or father of the baby)
* other condition amenable to noninvasive prenatal testing such as a single gene disorder (e.g., CF, sickle cell, Fragile X)

Exclusion Criteria:

* No fetal heart activity detected
* Mother or father have known chromosomal abnormalities (including known balanced translocations)
* Women with active or history of malignancy

Primary outcomes:
measure: Point estimates and 95% CIs for sensitivity, specificity, PPV, and NPV versus birth outcome (trisomy or Unaffected/non-trisomy) for the LDT in the population of pregnancies at mixed-risk for chromosomal abnormalities
timeFrame: about 3 years
Secondary outcomes:
measure: To estimate the false positive rate of the LDT versus birth outcome (trisomy or Unaffected/ non-trisomy) in a low-risk sub-population of pregnant women undergoing serum biochemical screening for fetal aneuploidy.
timeFrame: about 3 years
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Valley Perinatal
state: Arizona
city: Eunice
country: United States
facility: Heinen Obstectrics & Gynecology
state: Louisiana
city: Brooklyn
country: United States
facility: Newlife Wellness OBGYN
state: New York
city: Mooresville
country: United States
facility: Lakeshore Women's Specialists
state: North Carolina
city: Cincinnati
country: United States
facility: Cincinnati Obgyn
state: Ohio
city: Norwalk
country: United States
facility: James D. Kasten, M.D., Inc.
state: Ohio
city: Chattanooga
country: United States
facility: Regional Obstetrical Consultants
state: Tennessee
city: Webster
country: United States
facility: Texas Maternal-Fetal Medicine
state: Texas
Study officials:
affiliation: Head of Clinical Affairs
name: Peter Stiegler, PhD
role: STUDY_DIRECTOR
References: